Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/the-combination-of-fludarabine-cytarabine-and-etoposide-is-an-active-NU20jjkse6
References (33)
-
M. Litzow, M. Othus, L. Cripe, S. Gore, H. Lazarus, Sandra Lee, J. Bennett, E. Paietta, G. Dewald, J. Rowe, M. Tallman (2010)
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology GroupBritish Journal of Haematology, 148
-
M. Duval, J. Klein, Wensheng He, J. Cahn, M. Cairo, B. Camitta, R. Kamble, E. Copelan, M. Lima, Vikas Gupta, A. Keating, H. Lazarus, M. Litzow, D. Marks, R. Maziarz, D. Rizzieri, G. Schiller, K. Schultz, M. Tallman, D. Weisdorf (2010)
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 23
-
U. Creutzig, S. Diekamp, M. Zimmermann, D. Reinhardt (2007)
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AMLPediatric Blood & Cancer, 48
-
G. Rivera, T. Avery, D. Roberts (1975)
Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.European journal of cancer, 11 9
-
K. Ooi, T. Ohkubo, H. Kuwabara, M. Higashigawa, H. Kawasaki, H. Kakitoh, Y. Kagawa, S. Inagaki, K. Sumida, M. Sakurai (1993)
Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide.Cancer investigation, 11 4
-
W. Vogler, D. McCarley, M. Stagg, A. Bartolucci, Joseph Moore, O. Martelo, G. Omura (1994)
A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.Leukemia, 8 11
-
(1986)
arabinofuranosylcytosine in refractory leukemia -
A. Camera, C. Rinaldi, S. Palmieri, N. Cantore, G. Mele, V. Mettivier, E. Miraglia, L. Mastrullo, F. Grimaldi, L. Luciano, A. Guerriero, B. Rotoli, F. Ferrara (2009)
Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patientsAnnals of Hematology, 88
-
T. Ohkubo, M. Higashigawa, H. Kawasaki, H. Kamiya, M. Sakurai, Y. Kagawa, E. Kakito, K. Sumida, K. Ooi (1988)
Sequence-dependent antitumor effect of VP-16 and 1-beta-D-arabinofuranosylcytosine in L1210 ascites tumor.European journal of cancer & clinical oncology, 24 12
-
(1986)
Phase I - II clinical and pharmacologic studies of high - dose 143 - Darabi - nofuranosylcytosine in refractory leukemia -
N. Breslow, D. Cox, D. Oakes (1985)
Analysis of Survival Data.Biometrics, 41
-
J. Rowe, Xiaochun Li, P. Cassileth, F. Appelbaum, C. Schiffer, P. Wiernik, M. Litzow, L. Cripe, H. Lazarus, E. Paietta, G. Dewald, H. Weinstein, A. Ogden, W. Woods, L. Shepherd, J. Feusner, C. Bloomfield, M. Tallman (2005)
Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience.Blood, 106
-
D. Breems, W. Putten, P. Huijgens, G. Ossenkoppele, G. Verhoef, L. Verdonck, E. Vellenga, G. Greef, E. Jacky, J. Lelie, M. Boogaerts, B. Löwenberg (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 9
-
Y. Higashi, J. Turzanski, M. Pallis, N. Russell (2000)
Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara‐C) and granulocyte colony‐stimulating factor (FLAG) compared with daunorubicin and Ara‐C in P‐glycoprotein‐positive and P‐glycoprotein‐negative acute myeloblastic leukaemiaBritish Journal of Haematology, 111
-
E. Estey, W. Plunkett, D. Dixon, M. Keating, K. McCredie, E. Freireich (1987)
Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.Leukemia, 1 8
-
V. Gandhi, E. Estey, M. Keating, W. Plunkett (1993)
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 11 1
-
K. Ooi, T. Ohkubo, H. Kawasaki, M. Sakurai (1989)
[Studies on the relationship between therapeutic schedule and antitumor effect of etoposide and cytosine arabinoside in murine L1210 leukemia].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 109 11
-
H. Kohrt, Samit Patel, Michelle Ho, T. Owen, D. Pollyea, R. Majeti, J. Gotlib, S. Coutre, M. Liedtke, C. Berubé, Ash Alizadeh, B. Medeiros (2010)
Second‐line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single‐center experienceAmerican Journal of Hematology, 85
-
Michael Martin, K. Augustin, G. Uy, J. Welch, Lindsay Hladnik, S. Goyal, D. Tiwari, Ryan Monahan, R. Reichley, A. Cashen, K. Stockerl-Goldstein, P. Westervelt, C. Abboud, J. Dipersio, R. Vij (2009)
Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G‐CSFAmerican Journal of Hematology, 84
-
W. Hiddemann, C. Aul, G. Maschmeyer, R. Schönrock-Nabulsi, W. Ludwig, A. Bartholomäus, P. Bettelheim, K. Becker, L. Balleisen, B. Lathan (1993)
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison.Leukemia & lymphoma, 10 Suppl
-
Hawk Kim, Jae‐Hoo Park, Je-Hwan Lee, Jung-Hee Lee, Y. Joo, W. Lee, S. Bae, hun ryoo, K. Lee (2009)
Continuous infusion of intermediate‐dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: A prospective, multicenter phase II studyAmerican Journal of Hematology, 84
-
Jeff Davies (2013)
Reproduced with the permission of Bird life Australia and -
F. Ravandi, J. Cortes, S. Faderl, S. O'brien, G. Garcia-Manero, S. Verstovsek, F. Santos, J. Shan, M. Brandt, M. Lima, S. Pierce, H. Kantarjian (2009)
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.Blood, 116 26
-
Y. Ofran, J. Rowe (2012)
Treatment for relapsed acute myeloid leukemia: what is new?Current Opinion in Hematology, 19
-
E. Atallah, J. Cortes, S. O'brien, S. Pierce, M. Rios, E. Estey, M. Markman, M. Keating, E. Freireich, H. Kantarjian (2007)
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.Blood, 110 10
-
E. Feldman, J. Brandwein, R. Stone, M. Kalaycio, J. Moore, J. O'Connor, N. Wedel, G. Roboz, Carole Miller, R. Chopra, J. Jurcic, R. Brown, W. Ehmann, P. Schulman, S. Frankel, Daniel Angelo, D. Scheinberg (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 18
-
M. Michallet, X. Thomas, J. Vernant, M. Kuentz, G. Socié, H. Espérou-Bourdeau, N. Milpied, D. Blaise, B. Rio, J. Reiffers, Jouet Jp, J. Cahn, J. Bourhis, B. Lioure, M. Leporrier, J. Sotto, G. Souillet, L. Sutton, P. Bordigoni, F. Dreyfus, H. Tilly, N. Gratecos, M. Attal, P. Leprise, F. Demeocq, G. Michel, A. Buzyn, B. Delmas-Marsalet, F. Bernaudin, N. Ifrah, A. Sadoun, D. Guyotat, M. Cavazzana-Cavo, D. Caillot, T. Revel, J. Vannier, A. Baruchel, N. Fegueux, M. Tanguy, A. Thiébaut, A. Belhabri, E. Archimbaud (2000)
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)Bone Marrow Transplantation, 26
-
F. Giles, S. O'brien, J. Cortes, S. Verstovsek, C. Bueso-Ramos, J. Shan, S. Pierce, G. Garcia-Manero, M. Keating, H. Kantarjian (2005)
Outcome of patients with acute myelogenous leukemia after second salvage therapyCancer, 104
-
S. Faderl, M. Wetzler, D. Rizzieri, G. Schiller, M. Jagasia, R. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. Maris, T. Kovacsovics, S. Goldberg, K. Seiter, P. Hari, J. Greiner, N. Vey, C. Récher, F. Ravandi, E. Wang, M. Vasconcelles, D. Huebner, H. Kantarjian (2012)
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 20
-
W. Plunkett, J. Liliemark, T. Adams, B. Nowak, E. Estey, H. Kantarjian, M. Keating (1987)
Saturation of 1-β-d-Arabinofuranosylcytosine 5′-Triphosphate Accumulation in Leukemia Cells during High-Dose 1-β-d-Arabinofuranosylcytosine TherapyCancer Research, 47
-
R. Walter, M. Othus, G. Borthakur, F. Ravandi, J. Cortes, S. Pierce, F. Appelbaum, H. Kantarjian, E. Estey (2011)
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 33
-
J. Hołowiecki, S. Grosicki, S. Kyrcz‐Krzemień, A. Skotnicki, B. Piątkowska‐Jakubas, K. Warzocha, I. Seferyńska, B. Zdziarska (2008)
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot studyAnnals of Hematology, 87
-
P. Temming, A. Qureshi, J. Hardt, A. Leiper, G. Levitt, P. Ancliff, D. Webb (2011)
Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United KingdomPediatric Blood & Cancer, 56
- Publisher
- Karger
- Copyright
- © 2013 S. Karger AG, Basel
- ISSN
- 0001-5792
- eISSN
- 1421-9662
- DOI
- 10.1159/000354820
- Publisher site
- See Article on Publisher Site
Abstract
We retrospectively reviewed the outcome of 20 consecutive subjects with refractory/relapsed acute myeloid leukemia (AML; 9 refractory and 11 relapsed) treated at our institution with a fludarabine, cytarabine and etoposide (FCE) salvage regimen. Of 20 patients with refractory/relapsed AML, 15 (75%) achieved complete remission (CR)/CR with incomplete peripheral blood count recovery (CRi), including 14 CR and 1 CRi. The 4- and 8-week treatment-related mortality (TRM) for all patients during reinduction was 0 and 5%, respectively. Eight of 15 patients (53%) who successfully achieved CR were able to undergo allogeneic hematopoietic stem cell transplantation with a 0% non-relapse mortality rate. FCE is a new, well-tolerated, anthracycline-free regimen, which has a promising activity in relapsed/refractory AML and is associated with low TRM in this high-risk population.
Journal
Acta Haematologica – Karger
Published: Jan 1, 2013
Keywords: Acute myeloid leukemia; Cytarabine; Etoposide; Fludarabine; Relapse